ANDA 216599, held by Amneal. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 216599 (Doxycycline Hyclate), held by Amneal, was first approved by FDA on Oct 24, 2022, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 24, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Jan 26, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 30, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 24, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters